What does CUSIP 04351P101 represent in this 13F holders report?

CUSIP 04351P101 is the security identifier for ASND - Ascendis Pharma A/S - American Depositary Shares used to aggregate holder disclosures.

How many institutions held ASND - Ascendis Pharma A/S - American Depositary Shares in Q1 2017?

34 institutional investors reported ASND - Ascendis Pharma A/S - American Depositary Shares for Q1 2017. Use the holders table for investor-level position and value details.

Ascendis Pharma A/S - American Depositary Shares (ASND)

CUSIP: 04351P101

Q1 2017 13F Holders as of 31 Mar 2017

Type / Class: Equity / American Depositary Shares
Shares outstanding: 61,990,867
Total 13F shares: 20,898,775
Share change: +248,180
Total reported value: $585,169,000
Price per share: $28.00
Number of holders: 34
Value change: +$9,050,400
Number of buys: 16
Number of sells: 15

Quarterly Holders Quick Answers

What is CUSIP 04351P101?
CUSIP 04351P101 identifies ASND - Ascendis Pharma A/S - American Depositary Shares in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2017
Previous quarter: Q4 2016

Recent filing periods for CUSIP 04351P101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ASND - Ascendis Pharma A/S - American Depositary Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RA CAPITAL MANAGEMENT, L.P.	13F	Company	8.7%	5,409,990	$109,498,000	—	31 Dec 2016	13F
FMR LLC	13F	Company	5.1%	3,152,532	$63,807,000	—	31 Dec 2016	13F
ORBIMED ADVISORS LLC	13F	Company	4.4%	2,717,315	$54,998,000	—	31 Dec 2016	13F
Vivo Capital, LLC	13F	Company	2.9%	1,766,832	$35,761,000	—	31 Dec 2016	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	1.7%	1,050,000	$21,252,000	—	31 Dec 2016	13F
BAKER BROS. ADVISORS LP	13F	Company	1.7%	1,023,266	$20,711,000	—	31 Dec 2016	13F
EcoR1 Capital, LLC	13F	Company	1.6%	975,700	$19,748,000	—	31 Dec 2016	13F
VHCP Management II, LLC	13F	Company	1.2%	721,152	$14,596,000	—	31 Dec 2016	13F
JANUS HENDERSON INVESTORS US LLC	13F	Company	0.96%	594,295	$12,029,000	—	31 Dec 2016	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.93%	575,309	$11,644,000	—	31 Dec 2016	13F
Avoro Capital Advisors LLC	13F	Company	0.88%	545,203	$11,035,000	—	31 Dec 2016	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.53%	326,622	$6,611,000	—	31 Dec 2016	13F
Rock Springs Capital Management LP	13F	Company	0.52%	325,000	$6,578,000	—	31 Dec 2016	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	0.37%	229,000	$4,635,000	—	31 Dec 2016	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.37%	226,804	$4,591,000	—	31 Dec 2016	13F
Foresite Capital Management III, LLC	13F	Company	0.29%	180,000	$3,643,000	—	31 Dec 2016	13F
Cormorant Asset Management, LP	13F	Company	0.26%	162,254	$3,284,000	—	31 Dec 2016	13F
EMORY UNIVERSITY	13F	Company	0.17%	104,793	$2,121,000	—	31 Dec 2016	13F
NEXTHERA CAPITAL LP	13F	Company	0.16%	100,000	$2,024,000	—	31 Dec 2016	13F
VHCP Management, LLC	13F	Company	0.15%	90,000	$1,822,000	—	31 Dec 2016	13F
MARSHALL WACE, LLP	13F	Company	0.14%	87,558	$1,772,000	—	31 Dec 2016	13F
Laurion Capital Management LP	13F	Company	0.13%	83,200	$1,684,000	—	31 Dec 2016	13F
DAFNA Capital Management LLC	13F	Company	0.09%	53,000	$1,073,000	—	31 Dec 2016	13F
ALPS ADVISORS INC	13F	Company	0.05%	30,296	$613,000	—	31 Dec 2016	13F
HIGHBRIDGE CAPITAL MANAGEMENT LLC	13F	Company	0.03%	20,000	$405,000	—	31 Dec 2016	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.01%	5,247	$106,000	—	31 Dec 2016	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	4,325	$88,000	—	31 Dec 2016	13F
MORGAN STANLEY	13F	Company	0%	662	$13,000	—	31 Dec 2016	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	609	$12,000	—	31 Dec 2016	13F
UBS Group AG	13F	Company	0%	200	$4,000	—	31 Dec 2016	13F
US BANCORP \DE\	13F	Company	0%	76	$2,000	—	31 Dec 2016	13F

Institutional Holders of Ascendis Pharma A/S - American Depositary Shares (ASND) as of Q1 2017

As of 31 Mar 2017, Ascendis Pharma A/S - American Depositary Shares (ASND) was held by 34 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 20,898,775 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, LLC, FMR LLC, ORBIMED ADVISORS LLC, Vivo Capital, LLC, BAKER BROS. ADVISORS LP, EcoR1 Capital, LLC, DEERFIELD MANAGEMENT CO, VHCP Management II, LLC, venBio Select Advisor LLC, and JANUS CAPITAL MANAGEMENT LLC. This page lists 34 institutional shareholders reporting positions in this security for the Q1 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2017 vs Q4 2016 Across Filers

Q4 2016 holders

Q1 2017 holders

Holder diff

Investor	Q4 2016 Shares	Q1 2017 Shares	Share Diff	Share Chg %	Q4 2016 Value $	Q1 2017 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.